Summary

Summary As part of International HEOR & PCO in International Value & Access, the Patient Centered Outcomes (PCO) HTA, TA Director within the HEOR TA teams, in partnership with HEOR leads co-leads the PCO reimbursement strategy that enables measurements of patient centered outcomes to support robust payer value propositions and evidence for HTAs, optimizing international access for prioritized Novartis assets.
The PCO HTA TA Director will oversee one therapeutic area (e.g., CRM, immunology, oncology, or neurosciences) and their responsibility will span multiple assets/indications. Support and guidance to other members of the HEOR TA team for input or development of plans e.g. Health Technology Assessment Strategy Plans, Integrated Evidence Plans.

The PCO HTA TA Director will be leading the HEOR Patient Centered Outcomes strategy within a Therapeutic Area and will contribute to the OnePCO Strategy through direct interface with the Clinical Development PCO Center of Excellence (PCO COE) when novel or disease-specific PCOs are required.
In collaboration with regions and countries, The PCO HTA TA Director ensures that local PCO requirements are integrated into the PCO reimbursement strategy, and in the global and international evidence plans and PCO activities. Focus will be given to providing clear strategic rationale for and selection of health utility and other PROs for differentiation and translation to economic impact in partnership with HEOR. In addition, support the implementation of country-specific PCO evidence generation as needed to support access.
The Director, HEOR PCO, will serve as an internal expert on health utility assessment activities. She/he will also lead health state valuation projects via development and management of Time Trade-Off (TTO) or Standard Gamble (SG) studies where appropriate.
The PCO HTA TA Director will support HEOR TA on early scientific advice with HTAs e.g. EU HTA JSC and attend HTA meetings and/or support negotiations in collaboration with cross-functional and country team members. The Director will cultivate a strong partnership with team members from internal groups incl. Access, Clinical Development, PCO COE, AQS Biostat, Medical Affairs, and the International Commercial organization.
In addition, PCO HTA TA Director will represent Novartis externally and ensure thought leadership in collaboration with external partners (e.g. industry consortiums e.g., ISPOR, ISOQOL, PRO/Utility experts). Internally, the Director ensures within HEOR TA and Novartis to drive understanding of HTA requirements for PCO, health utility assessment, and adoption of standards and best practices.